Skip to main content
$0.100 -0.005 (-4.76%)

High

$0.11

Low

$0.10

Trades

225

Turnover

$176,834

Volume

1,754,344
30 June 2023 at 4:10pm
If you were already registered, log in here.

Short Interest

ASIC data, 29 Nov 2023

% Shorted

0.32%
vs 0.32% prior report

Most Shorted Rank

345th
of 717 shorted ASX stocks

Peak Short

3.79%
Dec 2022

Days to Cover

1.0
at 50d avg vol
Subject
IHL Ann: Application for quotation of securities - IHL

IHL Ann: Annual Report to Shareholders

IHL Ann: Appendix 4E & Financial Report for the year ended 30 June 21

IHL Ann: Application for quotation of securities - IHL

IHL Ann: Cleansing Notice - Options Exercise

IHL Ann: Notification regarding unquoted securities - IHL

IHL Ann: Notice of General Meeting/Proxy Form

IHL Ann: IHL files Form F-1 registration statement with SEC

IHL Ann: Cleansing Notice - Options Exercise

IHL Ann: Application for quotation of securities - IHL

IHL Ann: Incannex Psychedelic Therapies Presentation

IHL Ann: HREC and FDA pre-IND request for Psilocybin Therapy

IHL Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IHL Ann: IHL commences IHL-675A trial and patent application

IHL Ann: IHL-42X patent update & open label extension study approval

IHL Ann: Cleansing Notice and Appendix 2A - Options Exercise

IHL Ann: Trading Halt

IHL Ann: Incannex engages Procaps for production of IHL-675A

IHL Ann: Company Secretary Appointment/Resignation

IHL Ann: Diectors' Disclosures (4 x Appendix 3Y)

IHL Ann: Changes to Securities on Issue

IHL Ann: IHL-216A formulation and manufacturing appointment

IHL Ann: Escrow release

IHL Ann: Cleansing Notice and Appendix 2A

IHL Ann: Cleansing Notice and Apendix 2A - Options Exercise

IHL Ann: IHL-42X OSA Update

IHL Ann: Cleansing Notice and Appendix 2A - Options exercise

IHL Ann: Appendix 3Y - Peter Widdows

IHL Ann: Cleansing Notice and Appendix 2A - Options exercise

IHL Ann: Quarterly Activities Report - Mar21

IHL Ann: Positive FDA Pre-IND meeting guides IHL-675A development

IHL Ann: Cleansing Notice and Appendix 2A

IHL Ann: IHL-675A Pre-IND meeting with FDA update

IHL Ann: IHL-675A outperforms existing treatment for arthritis

IHL Ann: Trading Halt

IHL Ann: IHL-216A to be assessed in NFL model of concussion

IHL Ann: Cleansing Notice and Appendix 2A

IHL Ann: Change in Director's Interest

IHL Ann: Appendix 4D correction

IHL Ann: Cleansing Notice and Appendix 2A

IHL Ann: Appendix 3G

IHL Ann: Half Yearly Report and Accounts

IHL Ann: Proposed issue of Securities - IHL

IHL Ann: IHL-675A in vivo results for Inflammatory Bowel Disease

IHL Ann: Trading Halt

IHL Ann: IHL appoints EAS Advisors LLC to facilitate US listing

IHL Ann: IHL-675A in vivo results for COPD and asthma

IHL Ann: Quarterly Activities Report - Dec 2020

IHL Ann: Cleansing Notice and Appendix 2A

IHL Ann: Incannex AGM Presentation

If you were already registered, log in here.

Similar Companies

CAN
CPH
EOF
MVP
MYX
NEU
PBP
RCE
SPL
S88
MAV
CX8
MTX $12m raise
ATW $7.5m raise
RDO $30m raise
ABC $5m raise
RGS